Table 2A.

Grade ≥2 adverse events at least possibly related to study therapy in ≥5% of patients by cohort.

		Cohort A: P+B (n = 50)				Cohort B: P alone (n = 30)
	Grade	2 (%)	3 (%)	4 (%)	Total (%)	2 (%)	3 (%)	4 (%)	Total (%)
Event
Hypertension		15 (30)	10 (20)	0	25 (50)	0	0	0	0
Headache		4 (8)	4 (8)	0	8 (16)	6 (20)	3 (10)	0	9 (30)
Fatigue		9 (18)	0	0	9 (18)	5 (17)	0	0	5 (17)
Infection		6 (12)	1 (2)	0	7 (14)	0	0	0	0
Proteinuria		7 (14)	0	0	7 (14)	0	0	0	0
Arthralgia		4 (8)	0	0	4 (8)	1 (3)	0	0	1 (3)
Diarrhea		2 (4)	1 (2)	0	3 (6)	1 (3)	0	0	1 (3)
Seizures		3 (6)	0	0	3 (6)	2 (7)	0	0	2 (7)
Anorexia		1 (2)	0	0	1 (2)	2 (7)	0	0	2 (7)
Hyperglycemia		2 (4)	0	0	2 (4)	1 (3)	1 (3)	0	2 (7)
Lymphopenia		2 (4)	0	0	2 (4)	2 (7)	0	0	2 (7)

Abbreviations: B, bevacizumab; n, number; P, pembrolizumab.